Trial Profile

A Partially-blinded, Active-controlled, Multicenter, Randomized Study Evaluating Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in de Novo and Maintenance Kidney Transplant Recipients (CIRRUS I)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 13 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Iscalimab (Primary) ; Iscalimab (Primary) ; Corticosteroids; Mycophenolate mofetil; Mycophenolate mofetil; Prednisolone; Tacrolimus; Tacrolimus
Indications Renal transplant rejection
Focus Therapeutic Use
Acronyms CIRRUS I
Sponsors Novartis; Novartis Pharmaceuticals

10 Mar 2022 This trial has been discontinued in Italy (End Date: 29 Oct 2021), according to European Clinical Trials Database record.
12 Jan 2022 Status changed from active, no longer recruiting to completed.
04 Dec 2021 This trial has been completed in Sweden, according to European Clinical Trials Database record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com